Showing 4651-4660 of 6036 results for "".
- Visionix and Right MFG to Enter a Long-Term Strategic Partnershiphttps://modernod.com/news/visionix-and-right-mfg-to-enter-a-long-term-strategic-partnership/2480863/Visionix, formerly Luneau Technology, and Japan-based Right MFG announced today that they have entered a long-term strategic partnership agreement with the aim of accelerating growth for both companies. Financial terms of the deal were not disclosed.
- Alcon Celebrates 75th Anniversaryhttps://modernod.com/news/alcon-celebrates-75-years-of-eye-care-innovation/2480862/Alcon marked the company’s 75th anniversary this week with its "Brilliant History. Brilliant Future." celebration. On May 16, 1947, Alcon Laboratories Inc. was incorporated and began manufacturing specialty pharmaceutical products in Fort Worth, Texas. To
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Eyevensys Recaps Highlights from Investigator Meeting and Presentations at ARVOhttps://modernod.com/news/eyevensys-recaps-highlights-from-investigator-meeting-and-presentations-at-arvo/2480854/Eyevensys provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in its clinical trials
- MacuLogix Reaches Milestone with One Million Dark Adaptation Testshttps://modernod.com/news/maculogix-reaches-milestone-with-one-million-dark-adaptation-tests/2480853/MacuLogix announced that more than 1 million dark adaptation tests have been performed using either the company’s original AdaptDx or the head-mounted AdaptDx Pro guided by Theia. Both devices use the same proprietary technology to efficiently measure dark adaptatio
- iSTAR Medical Expands Commercial Rollout With First MINIject Surgeries in Switzerlandhttps://modernod.com/news/istar-medical-expands-commercial-rollout-with-first-miniject-surgeries-in-switzerland/2480852/iSTAR Medical announced that it has continued its commercial rollout expansion for MINIject® to Switzerland. MINIject® is iSTAR Medical’s MIGS implant and currently the only commercially available supraciliary MIGS device, according to the company. Swiss patients with open-angl
- Kala Pharmaceuticals Launches Its First Direct-to-Consumer Campaign to Increase Awareness of Dry Eye Flareshttps://modernod.com/news/kala-pharmaceuticals-launches-its-first-direct-to-consumer-campaign-to-increase-awareness-of-dry-eye-flares/2480850/Kala Pharmaceuticals, Inc. today announced the launch of its first direct-to-consumer (DTC) campaign, “There for the Flare.” The campaign leverages digital channels to educate patients about dry eye flares and EYSUVIS® (loteprednol etabonate ophthalmic suspension 0.25%) and encour
- Skye Bioscience Reports Enhanced IOP-Lowering of SBI-100 Formulationhttps://modernod.com/news/skye-bioscience-reports-enhanced-iop-lowering-of-sbi-100-formulation/2480846/Skye Bioscience announced that the peer-reviewed journal International Journal of Pharmaceutics published preclinical data demonstrating stronger and longer-lasting reduction of IOP when Skye’s proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the
- MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the ARVO 2022 Annual Meetinghttps://modernod.com/news/meiragtx-presents-clinical-data-on-botaretigene-sparoparvovec-for-the-treatment-of-x-linked-retinitis-pigmentosa-at-the-arvo-2022-annual-meeting/2480844/MeiraGTx Holdings plc announced that additional clinical data from the phase 1/2 trial of botaretigene sparoparvovec for the treatment of x-linked retinitis pigmentosa (XLRP) were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting in Denver, Colo
- Zeiss Offers New SLT Application for the Visulas Green Therapeutic Laserhttps://modernod.com/news/zeiss-offers-new-slt-application-for-the-visulas-green-therapeutic-laser/2480842/Zeiss Medical Technology announced that it now offers the new SLT add-on to its Visulas green laser, part of an integrated glaucoma workflow designed to advance safe and effective glaucoma treatment. The new SLT laser feature offers unique protocols that may im